Recombinant Anti-HER3 × Anti-EGFR Bispecific Antibody (TandAb) is a bispecific fusion protein with four binding sites, two of which bind to antigens of one kind of cells and the other two to the other kind of cells. TandAbs do not carry Fc domains. So they are smaller than whole IgGs or IgG-derived BsAbs but larger than BiTEs. Therefore, they have a shorter serum half-life than IgGs but remain longer in the circulation compared with BiTEs. This BsAb is capable of blocking HER3 as well as EGFR simultaneously. BsAb-mediated simultaneous interference with two (or more) RTK signaling pathways, by inactivating either the RTKs or their ligand, can reduce the possibility of such escape mechanisms and, hence, improve therapeutic efficacy. It was designed for the treatment of head and neck cancer, colorectal cancer
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.